The Hyderabad-based Divis Laboratories Limited on Wednesday said that its Unit-2 plant in Visakhapatnam, which has been under import alert for the past six months, has resolved all issues related to the observations made by the US Food and Drug Administration (USFDA) in its latest CGMP audit.
The successful implementation of the post-audit corrective plan is expected to pave the way for the lifting of the import alert, which was issued as the US drug regulator pointed some manufacturing-related issues in the said plant.
Responding to the news, the company scrip rose by 8.13 per cent to Rs 934 during